Cell Biotech Co

Cell Biotech Co Capital Intensity

The Capital Intensity Ratio of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is 257.07 %. In the previous year, Capital Intensity Ratio was 261.25 % — a change of -1.60% (lower).

Capital Intensity

257.07 %

YoY

-1.60%

Last updated:

Capital Intensity Ratio of Cell Biotech Co is 2025 257.07 % . Capital Intensity Ratio of Cell Biotech Co was 2024 261.25 % . It decreases by -1.60% lower compared to the previous year.

The Cell Biotech Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
179.15 KRW
Jan 1, 2019
235.65 KRW
Jan 1, 2020
231.01 KRW
Jan 1, 2021
240.81 KRW
Jan 1, 2022
229.27 KRW
Jan 1, 2023
218.71 KRW
Jan 1, 2024
261.25 KRW
Jan 1, 2025
257.07 KRW
The Cell Biotech Co Capital Intensity history
YEARCapital IntensityYoY
257.07 %-1.60%
261.25 %+19.45%
218.71 %-4.60%
229.27 %-4.79%
240.81 %+4.24%
231.01 %-1.97%
235.65 %+31.54%
179.15 %+13.38%
158.01 %+1.72%
155.35 %+2.58%
151.44 %+7.17%
141.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Capital Intensity Ratio of Cell Biotech Co is 257.07 % in 2025.

Capital Intensity Ratio of Cell Biotech Co changed from 261.25 % to 257.07 %, representing a -1.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Cell Biotech Co

All Key Metrics — Cell Biotech Co